Wang et al developed models for evaluating a patient with an osteosarcoma of an extremity. This can help to identify a patient who may benefit from more aggressive management. The authors are from First Affilitated Hospital of Sun Yat-Sen University in Guangdong, China.
Patient selection: extremity osteosarcoma, Enneking stage II or III (not I), presumably all Chinese
Outcome: 5-year survival without lung metastases (lung metastasis free survival, LMFS)
Pretreatment parameters:
(1) tumor diameter in centimeters
(2) age in years and serum alkaline phosphatase in IU/L (method not specified)
(3) absolute neutrophil count in 10^9/L
(4) platelet count in 10^9/L
|
Parameter |
Finding |
Points |
|
tumor diameter |
<= 8 cm |
0 |
|
|
> 8 cm |
2 |
|
age and ALP |
< 18 and ALP < 150 |
0 |
|
|
< 18 and ALP >= 150 |
1 |
|
|
>= 18 and ALP < 110 |
0 |
|
|
>= 18 and ALP >= 110 |
1 |
|
neutrophil count in 10^9 |
< 6.4 |
0 |
|
|
>= 6.4 |
1 |
|
platelet count in 10^9 |
< 300 |
0 |
|
|
>= 300 |
1 |
total score =
= SUM(points for all 4 parameters)
Interpretation:
• minimum score: 0
• maximum score: 5
• The higher the score the greater the risk of lung metastasis..
|
Total Score |
Risk Group |
5 Year Overall Survival |
|
0 or 1 |
Low |
96% |
|
2 or 3 |
intermediate |
79% |
|
4 or 5 |
High |
41% |
Performance:
• The area under the ROC curve was 0.66 (training set) and 0.69 (validation set).
Specialty: Hematology Oncology, Surgery, general, Surgery, orthopedic
